Kiniksa Pharmaceuticals reports Q3 2026 results and lifts 2026 ARCALYST revenue outlook

Kiniksa Pharmaceuticals announced third‑quarter 2026 revenue of $286.0 million, up about 58% year‑over‑year, and net income of $47.3 million. The company raised its full‑year 2026 ARCALYST net product revenue guidance to $1.045 billion‑$1.050 billion. It also reported ARCALYST penetration of 23% of the recurrent pericarditis patient pool and said Phase 3 data for its KPL‑387 candidate are expected in the second half of 2027.

The higher ARCALYST revenue guidance signals stronger future cash flow, which could prompt analysts to upgrade forecasts and lift the stock price. The guidance increase also expands the company’s runway for investing in its pipeline.

  • 1Q3 2026 total revenue was $286.0 million.
  • 2Q3 2026 net income was $47.3 million.
  • 3GAAP EPS for Q3 2026 was $0.56.
  • 4ARCALYST net product revenue for Q3 2026 was $286.0 million.
  • 52026 ARCALYST net product revenue guidance was raised to $1.045 billion‑$1.050 billion.
  • 6ARCALYST penetration reached 23% of the 14,000 multiple‑recurrence patients by quarter‑end.

Sources